The SCAP/SREBP pathway: A mediator of hepatic steatosis

Young Ah Moon

Research output: Contribution to journalReview articlepeer-review

66 Scopus citations


Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance, obesity, and dyslipidemia. NAFLD encompasses a wide range of states from the simple accumulation of triglycerides in the hepatocytes to serious states accompanied by inflammation and fibrosis in the liver. De novo lipogenesis has been shown to be a significant factor in the development of hepatic steatosis in insulin-resistant states. Sterol regulatory element binding protein-1c (SREBP-1c) is the main transcription factor that mediates the activation of lipogenesis, and SREBP cleavage activating protein (SCAP) is required for the activation of SREBPs. Here, recent animal studies that suggest SCAP as a therapeutic target for hepatic steatosis and hypertriglyceridemia are discussed.

Original languageEnglish (US)
Pages (from-to)6-10
Number of pages5
JournalEndocrinology and Metabolism
Issue number1
StatePublished - Mar 1 2017


  • Hypertriglyceridemia
  • Insulin resistance
  • Lipogenesis
  • Non-alcoholic fatty liver disease

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'The SCAP/SREBP pathway: A mediator of hepatic steatosis'. Together they form a unique fingerprint.

Cite this